{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:13:10Z","timestamp":1791465190015,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2051,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004930","name":"Funda\u00e7\u00e3o do C\u00e2ncer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004930","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/annonc\/mdu015","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T21:39:41Z","timestamp":1394487581000},"page":"831-836","source":"Crossref","is-referenced-by-count":54,"title":["Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial"],"prefix":"10.1016","volume":"25","author":[{"given":"J.","family":"Bines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Obadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.P.","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Quintella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.F.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu015_bb0010","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu015_bb0025","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3109\/02841860903117816","article-title":"Additive endocrine therapy for advanced breast cancer\u2014back to the future","volume":"48","author":"L\u00f8nning","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jama.2009.1204","article-title":"Lower-dose vs high dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase II randomized study","volume":"302","author":"Ellis","year":"2009","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdu015_bb0035","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1001\/jama.2009.1857","article-title":"The Global Breast Cancer Disparity: strategies for bridging the gap","volume":"302","author":"Souza","year":"2009","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdu015_bb0040","first-page":"1515","article-title":"Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients","volume":"2","author":"Lundgren","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu015_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01810736","article-title":"Megestrol acetate versus aminoglutethimide for metastatic breast cancer","volume":"14","author":"Lundgren","year":"1989","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu015_bb0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000227345","article-title":"Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and\/or aminoglutethimide","volume":"51","author":"Brufman","year":"1994","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdu015_bb0055","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1200\/jco.2006.24.18_suppl.10572","article-title":"Megestrol acetate after aromatase inhibitor failure in metastatic breast cancer","volume":"24","author":"Branco","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0060","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","article-title":"Activity of exemestane in metastatic breast cancer after failure of non-steroidal aromatase inhibitors: a phase II trial","volume":"18","author":"L\u00f8nning","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0065","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1200\/JCO.2005.04.1053","article-title":"Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Trial Group Trial N0032","volume":"24","author":"Ingle","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0070","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0075","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/B:BREA.0000004375.17920.0b","article-title":"A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases","volume":"82","author":"Howell","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu015_bb0085","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0959-8049(03)00199-0","article-title":"Fulvestrant (FaslodexTM) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials","volume":"39","author":"Mauriac","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu015_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-008-0141-z","article-title":"Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial","volume":"117","author":"Mauriac","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu015_bb0095","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu015_bb0100","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1078-0432.CCR-10-2021","article-title":"Androgen receptor expression and breast cancer survival in postmenopausal women","volume":"17","author":"Hu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu015_bb0105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1995.13.7.1572","article-title":"Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression","volume":"13","author":"Birrell","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0110","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1158\/0008-5472.CAN-04-3077","article-title":"Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate","volume":"65","author":"Buchanan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu015_bb0115","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0","article-title":"A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group","volume":"79","author":"Buzdar","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu015_bb0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1999.17.1.52","article-title":"Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group","volume":"17","author":"Goss","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0130","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0135","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/bcr2771","article-title":"Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)","volume":"12","author":"Thompson","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu015_bb0140","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdr593","article-title":"The sequential use of endocrine treatment for advanced breast cancer: where are we?","volume":"23","author":"Barrios","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu015_bb0145","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/cncr.23837","article-title":"Effective but cost prohibitive drugs in breast cancer treatment: a clinical review","volume":"113","author":"Bines","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu015_bb0150","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/annonc\/mdt216","article-title":"Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer","volume":"24","author":"Jonat","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/4\/831\/16703313\/mdu015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T16:05:58Z","timestamp":1625155558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0923753419365019"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}